FourWorld Capital Spotlights 90% Sales Collapse of Omeros Sole Product OMIDRIA in Past Two Months, Reflecting Company’s Weakening State

February 21, 2018

Responsive image

NEW YORK, Feb. 21, 2018 /PRNewswire/ — Investment adviser FourWorld Capital Management, which recently issued a research report analyzing the potential financial deterioration of biopharmaceutical company Omeros Corp. (Nasdaq: OMER), has uncovered new data showing that sales of the…

Category: Precious Metals